ArticleJournal of inflammation research2025
Impact of
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aimed to evaluate the effects of Methods: The cytotoxic effects of EgCF on RBL-2H3 cells were assessed using the Cell Counting Kit-8 assay. Degranulation activity was quantified by measuring β-hexosaminidase release. Morphological alterations and cytoskeletal changes were evaluated via toluidine blue staining and phalloidin-labeled confocal laser scanning microscopy. Apoptotic cell populations were quantified using flow cytometry. Results: EgCF at mass concentrations ranging from 0.5 to 5 mg/mL significantly enhanced cell proliferation. Higher EgCF concentrations were associated with increased morphological deformation, as evidenced by toluidine blue staining, and with significantly elevated β-hexosaminidase release compared to the control group (p < 0.01). Flow cytometry revealed a statistically significant increase in apoptosis rates in the treated groups (p < 0.01). Within 30 minutes of EgCF exposure, phalloidin staining showed notable cytoskeletal reorganization, including cellular wrinkling and pseudopodia extension. These morphological changes were partially reversed within 45 to 60 minutes. Conclusion: EgCF induces morphological transformation and promotes degranulation in mast cells, with the intensity of these responses correlating positively with EgCF concentration. These findings suggest a dose-dependent role of EgCF in modulating mast cell activity during parasitic hypersensitivity responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.